RP2

Phase 3Biologic

RReplimune Inc.

RP2 is one of 99 biologic programs targeting Patients With Solid Tumors. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Solid TumorsActive, not recruiting

High-Risk Oral Precancerous DiseaseRecruiting

Second-Line TherapyRecruiting

Esophageal AdenocarcinomaNot yet recruiting

Uveal MelanomaRecruiting

Patients With Solid TumorsPhase 1

Active, not recruiting

High-Risk Oral Precancerous DiseasePhase 2

Recruiting

Second-Line TherapyPhase 2

Recruiting

Esophageal AdenocarcinomaPhase 2

Not yet recruiting

Uveal MelanomaPhase 3

Recruiting

Competition

Competitive Landscape

70 competitors in Patients With Solid Tumors

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

13 2

Faslodex

FFresenius Kabi USA, LLC

Phase 3

2 3

Keytruda

Merck & Co.

Phase 2

7 4

Avastin

Roche

Phase 2

6 5

Opdivo

Bristol-Myers Squibb

Phase 2

5 6

Imfinzi

AstraZeneca

Phase 2

3 7

Eloxatin

Teva

Phase 2

2 8

Pemazyre

Incyte

Phase 2

1 9

Zaniducla

Jazz Pharmaceuticals

Phase 2

1 10

Lynparza

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Patients With Solid Tumors

NCT04336241

Q3 2028

Phase 2Recruiting

Second-Line Therapy

NCT05733598

Q1 2029

Phase 2Recruiting

High-Risk Oral Precancerous Disease

NCT06623110

Q4 2029

Phase 2Not yet recruiting

Esophageal Adenocarcinoma

NCT07059611

Clinical

Trials by Indication[1]

Esophageal Adenocarcinoma1 trial

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

Not yet recruiting·—·Phase 2·NCT07059611·34 enrolled

Patients With Solid Tumors1 trial

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Active, not recruiting·RReplimune Inc.·Phase 1·NCT04336241·36 enrolled

Second-line Therapy1 trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Recruiting·RReplimune Inc.·Phase 2·NCT05733598·60 enrolled

Bevacizumab1 trial

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Terminated·RReplimune Inc.·Phase 2·NCT05733611·5 enrolled

Uveal Melanoma1 trial

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Recruiting·RReplimune Inc.·Phase 2/3·NCT06581406·280 enrolled

1 more indication

High-Risk Oral Precancerous Disease1 trial

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

Recruiting·GGlenn J. Hanna·Phase 2·NCT06623110·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for RP2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RP2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RP2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Replimune Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: RReplimune Inc.

RP2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2028

Q1 2029

Q4 2029

Trials by Indication[1]

Esophageal Adenocarcinoma1 trial

Patients With Solid Tumors1 trial

Second-line Therapy1 trial

Bevacizumab1 trial

Uveal Melanoma1 trial

High-Risk Oral Precancerous Disease1 trial

References

Drug Info

Quick Facts

Related News